Junfen Zhang, Celeste M Boesjes, Laura Loman, Esmé Kamphuis, Margreet L E Romeijn, Lotte S Spekhorst, Inge Haeck, Lian F van der Gang, Coco C Dekkers, Lisa P van der Rijst, Albert J Oosting, Paula van Lumig, Anneke M T van Lynden-van Nes, Ron A Tupker, Annieke Nijssen, Annebeth Flinterman, Klaziena Politiek, Wouter R H Touwslager, Wianda A Christoffers, Shiarra M Stewart, Marijke Kamsteeg, Marlies de Graaf, Marjolein S de Bruin-Weller, Marie-Louise A Schuttelaar
BACKGROUND: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. OBJECTIVE: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years. METHODS: Data were extracted from the prospective, multicenter BioDay registry (October 2017 - 2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice...
April 21, 2024: Journal of the American Academy of Dermatology